Personalized Antisense Oligonucleotide Therapy(N-Lorem)

N/A

Report date: 2024/11/27 20:00:40
NME

Base Information

Drug NamePersonalized Antisense Oligonucleotide Therapy(N-Lorem)
Drug Alias NamenL-ATN1-002
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAtrophin 1 modulators
TargetsAtrophin 1
Therapy Area/IndicationsAtrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesN-Lorem FoundationColumbia University
China Registration ClassN/A

Develop Information

Active CompaniesN-Lorem FoundationColumbia University
Inactive CompaniesN/A
Active IndicationsAtrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A